Apolipoprotein B-100 and ApoA-II Kinetics as Determinants of Cellular Cholesterol Efflux

被引:19
|
作者
Chan, Dick C. [1 ]
Anh Hoang [3 ]
Barrett, P. Hugh R. [1 ,2 ]
Wong, Annett T. Y. [1 ]
Nestel, Paul J. [3 ]
Sviridov, Dmitri [3 ]
Watts, Gerald F. [1 ]
机构
[1] Univ Western Australia, Sch Med & Pharmacol, Royal Perth Hosp, Perth, WA 6847, Australia
[2] Univ Western Australia, Fac Engn Comp & Math, Crawley, WA 6009, Australia
[3] Baker Heart & Diabet Inst, Melbourne, Vic 3004, Australia
来源
基金
英国医学研究理事会;
关键词
HIGH-DENSITY-LIPOPROTEIN; METABOLIC SYNDROME; VISCERAL OBESITY; TRANSFER PROTEIN; LDL-APHERESIS; HUMAN-SERUM; TRANSPORT; PLASMA; MECHANISM; HUMANS;
D O I
10.1210/jc.2012-1522
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Cellular cholesterol efflux is a key step in reverse cholesterol transport and may depend on the metabolism of apolipoprotein (apo) B-100, apoA-I, and apoA-II. Objective: We examined the associations between cholesterol efflux and plasma concentrations and kinetics of very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL)-apoB-100, high-density lipoprotein (HDL)-apoA-I, and HDL-apoA-II in men. Design, Subjects, and Methods: Thirty men were recruited from the community with a wide range of body mass index. The capacity of plasma and HDL to efflux cholesterol was measured ex vivo. Apolipoprotein kinetics were measured using stable isotope techniques and multicompartmental modeling. Results: Cholesterol efflux to whole plasma was correlated with plasma levels of cholesterol, triglyceride, apoB-100, insulin, cholesteryl ester transfer protein, and lecithin-cholesterol acyltransferase, body mass index and waist circumference (P < 0.05 in all). Cholesterol efflux was inversely correlated with the fractional catabolic rate (FCR) of VLDL (r = -0.728), IDL (r = -0.662), and LDL-apoB-100 (r = -0.479) but positively correlated with the FCR (r = 0.438) and production rate (r = 0.468) of HDL-apoA-II. In multiple regression analysis, the concentration and FCR of VLDL-apoB-100 (beta-coefficient = 0.708 and -0.518, respectively) and IDL-apoB-100 (beta-coefficient = 0.354 and -0.447, respectively) were independent predictors of cholesterol efflux. The association of cholesterol efflux with apoB-100 metabolism was diminished after removal of apoB-100-containing lipoproteins from plasma prior to efflux. All associations, except for cholesteryl ester transfer protein, were lost when cholesterol efflux to isolated HDL was tested. Conclusions: The plasma concentration and kinetics of apoB-100-containing lipoproteins are significant predictors of the capacity of whole plasma to effect cellular cholesterol efflux. (J Clin Endocrinol Metab 97: E1658-E1666, 2012)
引用
收藏
页码:E1658 / E1666
页数:9
相关论文
共 50 条
  • [1] Genetic determinants of apolipoprotein B-100 kinetics
    Ng, Theodore W. K.
    Ooi, Esther M. M.
    Watts, Gerald F.
    Chan, Dick C.
    Barrett, P. Hugh R.
    CURRENT OPINION IN LIPIDOLOGY, 2010, 21 (02) : 141 - 147
  • [2] Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome
    Chan, DC
    Watts, GF
    Barrett, PHR
    O'Neill, FH
    Thompson, GR
    OBESITY RESEARCH, 2003, 11 (04): : 591 - 596
  • [3] Mast cell chymase degrades ApoE and ApoA-II in ApoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux
    Lee, M
    Calabresi, L
    Chiesa, G
    Franceschini, G
    Kovanen, PT
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (09) : 1475 - 1481
  • [4] VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100
    Zulewski, H
    Ninnis, R
    Miserez, AR
    Baumstark, MW
    Keller, U
    JOURNAL OF LIPID RESEARCH, 1998, 39 (02) : 380 - 387
  • [5] MARKEDLY ACCELERATED CATABOLISM OF APOLIPOPROTEIN A-II (APOA-II) AND HIGH-DENSITY-LIPOPROTEINS CONTAINING APOA-II IN CLASSIC LECITHIN - CHOLESTEROL ACYLTRANSFERASE DEFICIENCY AND FISH-EYE DISEASE
    RADER, DJ
    IKEWAKI, K
    DUVERGER, N
    SCHMIDT, H
    PRITCHARD, H
    FROHLICH, J
    CLERC, M
    DUMON, MF
    FAIRWELL, T
    ZECH, L
    SANTAMARINAFOJO, S
    BREWER, HB
    JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (01): : 321 - 330
  • [6] Apolipoprotein B-100 gene mutations and cholesterol control in German patients
    Loggen, U
    Boden, A
    Baron, H
    Schuster, H
    Tolle, R
    Netwich, U
    Dupon, C
    Müller-Myhsok, B
    Baron, H
    Luft, FC
    ATHEROSCLEROSIS, 2003, 166 (02) : 411 - 412
  • [7] DEGRADATION OF HUMAN APOLIPOPROTEIN B-100 BY APOLIPOPROTEIN(A)
    CHULKOVA, TM
    TERTOV, VV
    FEBS LETTERS, 1993, 336 (02) : 327 - 329
  • [8] Apolipoprotein B-100 kinetics in visceral obesity and the effects of weight reduction
    Riches, FM
    Watts, GF
    Hua, J
    Stewart, GR
    Naoumova, RP
    Barrett, PHR
    ATHEROSCLEROSIS, 1999, 144 : 80 - 80
  • [9] POLYMORPHISM OF APOLIPOPROTEIN-A-II (APOA-II) AMONG INBRED STRAINS OF MICE - RELATIONSHIP BETWEEN THE MOLECULAR TYPE OF APOA-II AND MOUSE SENILE AMYLOIDOSIS
    HIGUCHI, K
    KITAGAWA, K
    NAIKI, H
    HANADA, K
    HOSOKAWA, M
    TAKEDA, T
    BIOCHEMICAL JOURNAL, 1991, 279 : 427 - 433
  • [10] Decreased production and increased catabolism of apolipoprotein B-100 in apolipoprotein B-67/B-100 heterozygotes
    Welty, FK
    Lichtenstein, AH
    Barrett, PHR
    Dolnikowski, GG
    Ordovas, JM
    Schaefer, EJ
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (05) : 881 - 888